Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

- PMLiVE

Sanofi abandons inhaled insulin pact with Mannkind

Poor sales prompt return of Afrezza rights less than a year after its launch

Biosimilars in 2018: EU doctors’ perceptions of RA drug market

Published in pharmaphorum October 2015 by Laurent Chanroux

Research Partnership

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

- PMLiVE

Boehringer plans €500m biopharma expansion in Austria

New production facility in Vienna will create 400 jobs when it comes online in 2021

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

Eli Lilly HQ

Lilly’s Lantus ‘follow-on’ approved in the US

Basaglar is first insulin product to be licensed via the FDA's truncated 505(b)(2) pathway

Sanofi reception

Sanofi and Boehringer in $20bn asset swap negotiations

Want to exchange their consumer health and veterinary interests

dengue fever mosquito

Sanofi gets first approval for dengue vaccine

Wins green light for Dengvaxia in Mexico

- PMLiVE

Boehringer’s coughing beat box drives its message home

Throat hacking performance raises awareness of lung cancer symptom

Sanofi Espoir Foundation appoints new president

Xavier Darcos succeeds Jean-François Dehecq

EU flag

Second biosimilar anti-TNF nears EU market

SamsungBioepis' version of Enbrel recommended for approval by the CHMP

Sanofi reception

Sanofi and AstraZeneca agree massive compound swap deal

Will exchange over 200,000 compounds in a new open innovation collaboration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links